Tabula Rasa HealthCare (NASDAQ:TRHC) had its price target hoisted by research analysts at Citigroup to $100.00 in a research report issued on Thursday, The Fly reports. The firm currently has a “buy” rating on the stock. Citigroup’s price target indicates a potential upside of 31.93% from the company’s current price.

Several other research analysts have also weighed in on TRHC. Robert W. Baird upped their target price on shares of Tabula Rasa HealthCare from $50.00 to $65.00 and gave the stock an “outperform” rating in a research report on Monday, June 18th. Piper Jaffray Companies increased their price target on shares of Tabula Rasa HealthCare to $71.00 and gave the company an “overweight” rating in a research report on Wednesday, August 8th. Zacks Investment Research upgraded shares of Tabula Rasa HealthCare from a “hold” rating to a “buy” rating and set a $74.00 price target on the stock in a research report on Saturday, August 11th. BidaskClub lowered shares of Tabula Rasa HealthCare from a “strong-buy” rating to a “buy” rating in a research report on Saturday, September 15th. Finally, Stifel Nicolaus began coverage on shares of Tabula Rasa HealthCare in a research report on Tuesday, September 11th. They issued a “hold” rating and a $95.00 price target on the stock. Three equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $71.75.

Shares of TRHC opened at $75.80 on Thursday. The company has a current ratio of 0.36, a quick ratio of 0.33 and a debt-to-equity ratio of 0.11. Tabula Rasa HealthCare has a twelve month low of $24.24 and a twelve month high of $91.16. The stock has a market cap of $1.64 billion, a price-to-earnings ratio of -1,895.00, a P/E/G ratio of 6.13 and a beta of 2.85.

Tabula Rasa HealthCare (NASDAQ:TRHC) last issued its earnings results on Tuesday, August 7th. The company reported $0.20 earnings per share for the quarter, topping the consensus estimate of $0.08 by $0.12. Tabula Rasa HealthCare had a negative net margin of 16.78% and a positive return on equity of 4.55%. The company had revenue of $48.60 million for the quarter, compared to analyst estimates of $46.73 million. Equities analysts anticipate that Tabula Rasa HealthCare will post 0.53 EPS for the current year.

In other news, President Orsula V. Knowlton sold 8,000 shares of the stock in a transaction that occurred on Friday, August 17th. The shares were sold at an average price of $72.23, for a total value of $577,840.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Insiders sold 48,000 shares of company stock worth $3,522,000 over the last quarter. Company insiders own 14.00% of the company’s stock.

Several hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. grew its position in shares of Tabula Rasa HealthCare by 29.7% in the second quarter. BlackRock Inc. now owns 2,119,507 shares of the company’s stock valued at $135,288,000 after purchasing an additional 484,979 shares during the last quarter. Jennison Associates LLC boosted its position in Tabula Rasa HealthCare by 29.5% during the second quarter. Jennison Associates LLC now owns 757,846 shares of the company’s stock worth $48,373,000 after acquiring an additional 172,693 shares during the last quarter. NN Investment Partners Holdings N.V. acquired a new stake in Tabula Rasa HealthCare during the second quarter worth approximately $29,439,000. Braun Stacey Associates Inc. boosted its position in Tabula Rasa HealthCare by 199.0% during the second quarter. Braun Stacey Associates Inc. now owns 301,089 shares of the company’s stock worth $19,219,000 after acquiring an additional 200,394 shares during the last quarter. Finally, Northern Trust Corp boosted its position in Tabula Rasa HealthCare by 52.3% during the second quarter. Northern Trust Corp now owns 227,503 shares of the company’s stock worth $14,522,000 after acquiring an additional 78,112 shares during the last quarter. Institutional investors and hedge funds own 75.15% of the company’s stock.

Tabula Rasa HealthCare Company Profile

Tabula Rasa HealthCare, Inc operates as a healthcare technology company in the United States. It offers medication risk management, pharmacy cost management, and medicare risk adjustment services. The company offers its technology-enabled products and services to prescribers, pharmacists, and healthcare organizations for medication risk management and risk adjustment.

Read More: What is the S&P 500 Index?

The Fly

Analyst Recommendations for Tabula Rasa HealthCare (NASDAQ:TRHC)

Receive News & Ratings for Tabula Rasa HealthCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa HealthCare and related companies with MarketBeat.com's FREE daily email newsletter.